It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Autism spectrum disorder (ASD) is a neurodevelopmental condition with onset in early childhood, still diagnosed only through clinical observation due to the lack of laboratory biomarkers. Early detection strategies would be especially useful in screening high-risk newborn siblings of children already diagnosed with ASD. We performed RNA sequencing on peripheral blood, comparing 27 pairs of ASD children vs their sex- and age-matched unaffected siblings. Differential gene expression profiling, performed applying an unpaired model found two immune genes, EGR1 and IGKV3D-15, significantly upregulated in ASD patients (both p adj = 0.037). Weighted gene correlation network analysis identified 18 co-expressed modules. One of these modules was downregulated among autistic individuals (p = 0.035) and a ROC curve using its eigengene values yielded an AUC of 0.62. Genes in this module are primarily involved in transcriptional control and its hub gene, RACK1, encodes for a signaling protein critical for neurodevelopment and innate immunity, whose expression is influenced by various hormones and known "endocrine disruptors". These results indicate that transcriptomic biomarkers can contribute to the sensitivity of an intra-familial multimarker panel for ASD and provide further evidence that neurodevelopment, innate immunity and transcriptional regulation are key to ASD pathogenesis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Mafalda Luce Center for Pervasive Developmental Disorders, Milan, Italy
2 The Translational Genomics Research Institute, Neurogenomics Division, Phoenix, USA (GRID:grid.250942.8) (ISNI:0000 0004 0507 3225)
3 IRCCS San Raffaele Scientific Institute, Center for Translational Genomics and Bioinformatics, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884)
4 Mafalda Luce Center for Pervasive Developmental Disorders, Milan, Italy (GRID:grid.18887.3e)
5 Mafalda Luce Center for Pervasive Developmental Disorders, Milan, Italy (GRID:grid.18887.3e); Synlab Suisse SA, Department of Genetics, Bioggio, Switzerland (GRID:grid.18887.3e)
6 Istituto Superiore di Sanità, Research Coordination and Support Service, Rome, Italy (GRID:grid.416651.1) (ISNI:0000 0000 9120 6856)
7 University of Modena and Reggio Emilia, Child and Adolescent Neuropsychiatry Program, Department of Biomedical, Metabolic and Neural Sciences, Modena, Italy (GRID:grid.7548.e) (ISNI:0000000121697570)